Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema

Trial Profile

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs BCX 7353 (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms APEX-2
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 30 Nov 2018 This trial was completed in Denmark (end date: 2018-10-24), according to European Clinical Trials Database.
    • 27 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Nov 2018 According to BioCryst Pharmaceuticals media release, APeX-2 study enrollment completed, results on-track for Q2 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top